Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 2545031, 10 pages
https://doi.org/10.1155/2017/2545031
Review Article

Metabolic Alterations of Thyroid Cancer as Potential Therapeutic Targets

1School of Human and Social Science, University “Kore” of Enna, Enna, Italy
2Centro Scienze dell’Invecchiamento e Medicina Traslazionale (CeSI-Met), Chieti, Italy
3Endocrinology Section, Department of Clinical and Experimental Medicine, Garibaldi-Nesima Hospital, University of Catania, Catania, Italy

Correspondence should be addressed to Veronica Vella; ti.erokinu@allev.acinorev

Received 31 May 2017; Accepted 15 October 2017; Published 6 November 2017

Academic Editor: Yujiang Fang

Copyright © 2017 Domenico Ciavardelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Eszlinger and R. Paschke, “Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns,” Molecular and Cellular Endocrinology, vol. 322, no. 1-2, pp. 29–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. C. J. El-Naggar, J. R. Grandis, T. Takata, and P. J. Slootweg, “World Health Organization classification of head and neck tumours,” in World Health Organization Classification of Tumours, vol. 9, 4th edition, 2017. View at Google Scholar
  3. K. Furukawa, D. Preston, S. Funamoto et al., “Long-term trend of thyroid cancer risk among Japanese atomic-bomb survivors: 60 years after exposure,” International Journal of Cancer, vol. 132, no. 5, pp. 1222–1226, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Bacher-Stier, G. Riccabona, M. Tötsch, G. Kemmler, W. Oberaigner, and R. Moncayo, “Incidence and clinical characteristics of thyroid carcinoma after iodine prophylaxis in an endemic goiter country,” Thyroid, vol. 7, no. 5, pp. 733–741, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Leenhardt and P. Grosclaude, “Epidemiology of thyroid carcinoma over the world,” Annales d'Endocrinologie, vol. 72, no. 2, pp. 136–148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Noguchi, A. Noguchi, and N. Murakami, “Papillary carcinoma of the thyroid I. Developing pattern of metastasis,” Cancer, vol. 26, no. 5, pp. 1053–1060, 1970. View at Publisher · View at Google Scholar · View at Scopus
  7. C. C. Lubitz and J. A. Sosa, “The changing landscape of papillary thyroid cancer: epidemiology, management, and the implications for patients,” Cancer, vol. 122, no. 24, pp. 3754–3759, 2016. View at Publisher · View at Google Scholar
  8. Y. C. Oertel, “Some thoughts about fine needle aspirations of thyroid nodules,” Thyroid: official journal of the American Thyroid Association, vol. 14, no. 1, pp. 86-87, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Kebebew and O. H. Clark, “Medullary thyroid cancer,” Current Treatment Options in Oncology, vol. 1, no. 4, pp. 359–367, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Z. Ali and E. S. Cibas, “The bethesda system for reporting thyroid Cytopathology II,” Acta Cytologica, vol. 60, no. 5, pp. 397-398, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Nagayama, M. Shimamura, and N. Mitsutake, “Cancer stem cells in the thyroid,” Frontiers in Endocrinology, vol. 7, article 20, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Malaguarnera, F. Frasca, A. Garozzo et al., “Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 3, pp. 766–774, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Gianì, V. Vella, M. L. Nicolosi et al., “Thyrospheres from normal or malignant thyroid tissue have different biological, functional, and genetic features,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 9, pp. E1168–E1178, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. B.-W. Dong, G.-M. Qin, Y. Luo, and J.-S. Mao, “Metabolic enzymes: Key modulators of functionality in cancer stem-like cells,” Oncotarget , vol. 8, no. 8, pp. 14251–14267, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Ciavardelli, M. Bellomo, C. Crescimanno, and V. Vella, “Type 3 deiodinase: Role in cancer growth, stemness, and metabolism,” Frontiers in Endocrinology, vol. 5, article 215, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Rivera, R. A. Ghossein, H. Schoder, D. Gomez, S. M. Larson, and R. M. Tuttle, “Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma,” Cancer, vol. 113, no. 1, pp. 48–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. S. J. Kim, M.-C. Kwon, M. J. Ryu et al., “CRIF1 is essential for the synthesis and insertion of oxidative phosphorylation polypeptides in the mammalian mitochondrial membrane,” Cell Metabolism, vol. 16, no. 2, pp. 274–283, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Karbownik-Lewińska and A. Kokoszko-Bilska, “Oxidative damage to macromolecules in the thyroid - experimental evidence,” Thyroid Research, vol. 5, no. 1, article 25, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. B. R. Rovcanin, K. R. Gopcevic, D. L. Kekic, V. R. Zivaljevic, A. D. Diklic, and I. R. Paunovic, “Papillary thyroid carcinoma: A malignant tumor with increased antioxidant defense capacity,” The Tohoku Journal of Experimental Medicine, vol. 240, no. 2, pp. 101–111, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. M. G. V. Heiden, L. C. Cantley, and C. B. Thompson, “Understanding the warburg effect: the metabolic requirements of cell proliferation,” Science, vol. 324, no. 5930, pp. 1029–1033, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. N. C. Denko, “Hypoxia, HIF1 and glucose metabolism in the solid tumour,” Nature Reviews Cancer, vol. 8, no. 9, pp. 705–713, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Zhang, M. Bosch-Marce, L. A. Shimoda et al., “Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia,” The Journal of Biological Chemistry, vol. 283, no. 16, pp. 10892–10903, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Burrows, J. Resch, R. L. Cowen et al., “Expression of hypoxia-inducible factor 1α in thyroid carcinomas,” Endocrine-Related Cancer, vol. 17, no. 1, pp. 61–72, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Klaus, O. Fathi, T. Tatjana, N. Bruno, and K. Oskar, “Expression of hypoxia-associated protein HIF-1α in follicular thyroid cancer is associated with distant metastasis,” Pathology & Oncology Research, 2017. View at Publisher · View at Google Scholar
  25. N. Burrows, M. Babur, J. Resch, K. J. Williams, and G. Brabant, “Hypoxia-inducible factor in thyroid carcinoma,” Journal of Thyroid Research, vol. 2011, Article ID 762905, 17 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Chen, M. Shen, Y. Li et al., “GC-MS-based metabolomic analysis of human papillary thyroid carcinoma tissue,” International Journal of Molecular Medicine, vol. 36, no. 6, pp. 1607–1614, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. J. H. Nahm, H. M. Kim, and J. S. Koo, “Glycolysis-related protein expression in thyroid cancer,” Tumor Biology, vol. 39, no. 3, 2017. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Grabellus, J. Nagarajah, A. Bockisch, K. W. Schmid, and S.-Y. Sheu, “Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma,” Clinical Nuclear Medicine, vol. 37, no. 2, pp. 121–127, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. R. S. Haber, K. R. Weiser, A. Pritsker, I. Reder, and D. E. Burstein, “Glut1 glucose transporter expression in benign and malignant thyroid nodules,” Thyroid, vol. 7, no. 3, pp. 363–667, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Pavlides, D. Whitaker-Menezes, R. Castello-Cros et al., “The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma,” Cell Cycle, vol. 8, no. 23, pp. 3984–4001, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. J. M. Curry, P. Tassone, P. Cotzia et al., “Multicompartment metabolism in papillary thyroid cancer,” The Laryngoscope, vol. 126, no. 10, pp. 2410–2418, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. K. S. Gill, P. Tassone, J. Hamilton et al., “Thyroid cancer metabolism: a review,” Journal of Thyroid Disorders & Therapy, vol. 5, no. 1, 2016. View at Google Scholar
  33. C. Feng, Y. Gao, C. Wang et al., “Aberrant Overexpression of Pyruvate Kinase m2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 9, pp. E1524–E1533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. H. M. Kim, Y. K. Lee, and J. S. Koo, “Expression of glutamine metabolism-related proteins in thyroid cancer,” Oncotarget , vol. 7, no. 33, pp. 53628–53641, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. M. H. Lee, S. E. Lee, D. W. Kim et al., “Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: A clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 1, pp. E19–E30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. G. N. Bijur and R. S. Jope, “Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation,” Journal of Neurochemistry, vol. 87, no. 6, pp. 1427–1435, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Morani, S. Phadngam, C. Follo et al., “PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells,” Molecular Endocrinology, vol. 53, no. 2, pp. 247–258, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. W. Kim, I. G. Do, and Y.-K. Park, “Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas,” Pathology - Research and Practice, vol. 202, no. 11, pp. 759–765, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Schwartzenberg-Bar-Yoseph, M. Armoni, and E. Karnieli, “The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression,” Cancer Research, vol. 64, no. 7, pp. 2627–2633, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Xing, “BRAF mutation in thyroid cancer,” Endocrine-Related Cancer, vol. 12, no. 2, pp. 245–262, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Xing, W. H. Westra, R. P. Tufano et al., “BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 12, pp. 6373–6379, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. B. Smith, X. L. Schafer, A. Ambeskovic, C. M. Spencer, H. Land, and J. Munger, “Addiction to Coupling of the Warburg Effect with Glutamine Catabolism in Cancer Cells,” Cell Reports, vol. 17, no. 3, pp. 821–836, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. Z. Liu, P. Hou, M. Ji et al., “Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 8, pp. 3106–3116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. X. Zhu, L. Zhao, J. W. Park, M. C. Willingham, and S.-Y. Cheng, “Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation,” Neoplasia, vol. 16, no. 9, pp. 757–769, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Carracedo and P. P. Pandolfi, “The PTEN-PI3K pathway: Of feedbacks and cross-talks,” Oncogene, vol. 27, no. 41, pp. 5527–5541, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. M.-M. Georgescu, “Pten tumor suppressor network in PI3K-Akt pathway control,” Genes & Cancer, vol. 1, no. 12, pp. 1170–1177, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. D. L. Segev, C. Umbricht, and M. A. Zeiger, “Molecular pathogenesis of thyroid cancer,” Surgical Oncology, vol. 12, no. 2, pp. 69–90, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Malaguarnera, V. Vella, R. Vigneri, and F. Frasca, “p53 family proteins in thyroid cancer,” Endocrine-Related Cancer, vol. 14, no. 1, pp. 43–60, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Malaguarnera, V. Vella, G. Pandini et al., “TAp73α increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation,” Molecular Cancer Research, vol. 6, no. 1, pp. 64–77, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Vella, C. Puppin, G. Damante et al., “ΔNp73α inhibits PTEN expression in thyroid cancer cells,” International Journal of Cancer, vol. 124, no. 11, pp. 2539–2548, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Morani, S. Phadngam, C. Follo et al., “PTEN deficiency and mutant p53 confer glucose-addiction to thyroid cancer cells: Impact of glucose depletion on cell proliferation, cell survival, autophagy and cell migration,” Genes & Cancer, vol. 5, no. 7-8, pp. 226–239, 2014. View at Google Scholar · View at Scopus
  52. I. Garcia-Cao, M. S. Song, R. M. Hobbs et al., “Systemic elevation of PTEN induces a tumor-suppressive metabolic state,” Cell, vol. 149, no. 1, pp. 49–62, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. C. R. Berkers, O. D. K. Maddocks, E. C. Cheung, I. Mor, and K. H. Vousden, “Metabolic regulation by p53 family members,” Cell Metabolism, vol. 18, no. 5, pp. 617–633, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Bläser, S. Maschauer, T. Kuwert, and O. Prante, “In vitro studies on the signal transduction of thyroidal uptake of 18F-FDG and131I-iodide,” Journal of Nuclear Medicine, vol. 47, no. 8, pp. 1382–1388, 2006. View at Google Scholar · View at Scopus
  55. A. Frilling, K. Tecklenborg, R. Görges, F. Weber, M. Clausen, and E. C. Broelsch, “Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma,” Annals of Surgery, vol. 234, no. 6, pp. 804–811, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Kondo, S. Ezzat, and S. L. Asa, “Pathogenetic mechanisms in thyroid follicular-cell neoplasia,” Nature Reviews Cancer, vol. 6, no. 4, pp. 292–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. F. Frasca, V. Vella, M. L. Nicolosi et al., “Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 6, pp. 2502–2512, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Kachel, B. Trojanowicz, C. Sekulla, H. Prenzel, H. Dralle, and C. Hoang-Vu, “Phosphorylation of pyruvate kinase M2 and lactate dehydrogenase A by fibroblast growth factor receptor 1 in benign and malignant thyroid tissue,” BMC Cancer, vol. 15, no. 1, article 140, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Malaguarnera, M. L. Nicolosi, A. Sacco et al., “Novel cross-talk between IGF-IR and DDR1 regulates IGF-IR trafficking, signaling and biological responses,” Oncotarget , vol. 6, no. 18, pp. 16084–16105, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Matà, C. Palladino, M. L. Nicolosi et al., “IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway,” Oncotarget , vol. 7, no. 7, pp. 7683–7700, 2016. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Rammal, C. Saby, K. Magnien et al., “Discoidin domain receptors: Potential actors and targets in cancer,” Frontiers in Pharmacology, vol. 7, article 55, 2016. View at Publisher · View at Google Scholar · View at Scopus
  62. T. N. Seyfried, R. E. Flores, A. M. Poff, and D. P. D'Agostino, “Cancer as a metabolic disease: implications for novel therapeutics,” Carcinogenesis, vol. 35, no. 3, pp. 515–527, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. D. S. Wishart, “Emerging applications of metabolomics in drug discovery and precision medicine,” Nature Reviews Drug Discovery, vol. 15, no. 7, pp. 473–484, 2016. View at Publisher · View at Google Scholar
  64. M. Yang, T. Soga, and P. J. Pollard, “Oncometabolites: Linking altered metabolism with cancer,” The Journal of Clinical Investigation, vol. 123, no. 9, pp. 3652–3658, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. D. B. Liesenfeld, N. Habermann, R. W. Owen et al., Review of Mass Spectrometry-Based Metabolomics in Cancer Research. Cancer Epidemiology, Biomarkers & Prevention: A Publication of The American Association for Cancer Research, Cosponsored by The American Society of Preventive Oncology, vol. 22(12), 2013.
  66. L. Torregrossa, L. Shintu, J. Nambiath Chandran et al., “Toward the reliable diagnosis of indeterminate thyroid lesions: a HRMAS NMR-based metabolomics case of study,” Journal of Proteome Research, vol. 11, no. 6, pp. 3317–3325, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Deja, T. Dawiskiba, W. Balcerzak et al., “Follicular adenomas exhibit a unique metabolic profile. 1H NMR studies of thyroid lesions,” PLoS ONE, vol. 8, no. 12, article e84637, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. Tian, X. Nie, S. Xu et al., “Integrative metabonomics as potential method for diagnosis of thyroid malignancy,” Scientific Reports, vol. 5, article 14869, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Xu, X. Zheng, Y. Qiu, W. Jia, J. Wang, and S. Yin, “Distinct Metabolomic Profiles of Papillary Thyroid Carcinoma and Benign Thyroid Adenoma,” Journal of Proteome Research, vol. 14, no. 8, pp. 3315–3321, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Wojakowska, M. Chekan, Ł. Marczak et al., “Detection of metabolites discriminating subtypes of thyroid cancer: Molecular profiling of FFPE samples using the GC/MS approach,” Molecular and Cellular Endocrinology, vol. 417, pp. 149–157, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. I. Ryoo, H. Kwon, S. C. Kim et al., “Metabolomic analysis of percutaneous fine-needle aspiration specimens of thyroid nodules: Potential application for the preoperative diagnosis of thyroid cancer,” Scientific Reports, vol. 6, article 30075, 2016. View at Publisher · View at Google Scholar · View at Scopus
  72. J. R. Doherty and J. L. Cleveland, “Targeting lactate metabolism for cancer therapeutics,” The Journal of Clinical Investigation, vol. 123, no. 9, pp. 3685–3692, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. Y.-J. Chen, N. G. Mahieu, X. Huang et al., “Lactate metabolism is associated with mammalian mitochondria,” Nature Chemical Biology, vol. 12, no. 11, pp. 937–943, 2016. View at Publisher · View at Google Scholar · View at Scopus
  74. M. L. Goodwin, L. B. Gladden, M. W. Nijsten, and K. B. Jones, “Lactate and cancer: revisiting the warburg effect in an era of lactate shuttling,” Frontiers in Nutrition, vol. 1, article 27, 2014. View at Publisher · View at Google Scholar
  75. F. Végran, R. Boidot, C. Michiels, P. Sonveaux, and O. Feron, “Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kB/IL-8 pathway that drives tumor angiogenesis,” Cancer Research, vol. 71, no. 7, pp. 2550–2560, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. D. R. Wise and C. B. Thompson, “Glutamine addiction: a new therapeutic target in cancer,” Trends in Biochemical Sciences, vol. 35, no. 8, pp. 427–433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. J. W. Locasale, “Serine, glycine and one-carbon units: cancer metabolism in full circle,” Nature Reviews Cancer, vol. 13, no. 8, pp. 572–583, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. I. Amelio, F. Cutruzzolá, A. Antonov, M. Agostini, and G. Melino, “Serine and glycine metabolism in cancer,” Trends in Biochemical Sciences, vol. 39, no. 4, pp. 191–198, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. W. Y. Sun, H. M. Kim, W.-H. Jung, and J. S. Koo, “Expression of serine/glycine metabolism-related proteins is different according to the thyroid cancer subtype,” Journal of Translational Medicine, vol. 14, no. 1, article no. 168, 2016. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Guo, Y. Wang, D. Zhou, and Z. Li, “Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging,” Scientific Reports, vol. 4, article no. 5959, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Guo, L. Qiu, Y. Wang et al., “Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry,” Analytical and Bioanalytical Chemistry, vol. 406, no. 18, pp. 4357–4370, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. Y. Ide, M. Waki, T. Hayasaka et al., “Human Breast cancer tissues contain abundant phosphatidylcholine(36:1) with high stearoyl-CoA desaturase-1 expression,” PLoS ONE, vol. 8, no. 4, article e61204, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. N. Gupta, B. Goswami, V. Chowdhury, L. RaviShankar, and A. Kakar, “Evaluation of the role of magnetic resonance spectroscopy in the diagnosis of follicular malignancies of thyroid,” JAMA Surgery, vol. 146, no. 2, pp. 179–182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. A. D. King, D. K. W. Yeung, A. T. Ahuja et al., “In vivo 1H MR spectroscopy of thyroid carcinoma,” European Journal of Radiology, vol. 54, no. 1, pp. 112–117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. U. E. Martinez-Outschoorn, M. Peiris-Pagés, R. G. Pestell, F. Sotgia, and M. P. Lisanti, “Cancer metabolism: a therapeutic perspective,” Nature Reviews Clinical Oncology, vol. 14, no. 1, pp. 11–31, 2016. View at Publisher · View at Google Scholar · View at Scopus
  86. Y. Zhao, E. B. Butler, and M. Tan, “Targeting cellular metabolism to improve cancer therapeutics,” Cell Death & Disease, vol. 4, no. 3, article e532, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. J. M. Curry, M. Tuluc, D. Whitaker-Menezes et al., “Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer,” Cell Cycle, vol. 12, no. 9, pp. 1371–1384, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Bikas, K. Jensen, A. Patel et al., “Glucose-deprivation increases thyroid cancer cells sensitivity to metformin,” Endocrine-Related Cancer, vol. 22, no. 6, pp. 919–932, 2015. View at Publisher · View at Google Scholar · View at Scopus
  89. L. K. Boroughs and R. J. Deberardinis, “Metabolic pathways promoting cancer cell survival and growth,” Nature Cell Biology, vol. 17, no. 4, pp. 351–359, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. R. J. DeBerardinis and N. S. Chandel, “Fundamentals of cancer metabolism,” Science Advances, vol. 2, no. 5, pp. e1600200–e1600200, 2016. View at Publisher · View at Google Scholar
  91. P. Danhier, P. Bański, V. L. Payen et al., “Cancer metabolism in space and time: Beyond the Warburg effect,” Biochimica et Biophysica Acta (BBA) - Bioenergetics, 2017. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Romero-Garcia, M. M. Moreno-Altamirano, H. Prado-Garcia, and F. J. Sánchez-García, “Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance,” Frontiers in Immunology, vol. 7, article no. 52, 2016. View at Publisher · View at Google Scholar
  93. L. Jiang and R. J. Deberardinis, “Cancer metabolism: when more is less,” Nature, vol. 489, no. 7417, pp. 511-512, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. M. G. Vander Heiden, H. R. Christofk, E. Schuman et al., “Identification of small molecule inhibitors of pyruvate kinase M2,” Biochemical Pharmacology, vol. 79, no. 8, pp. 1118–1124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Deshmukh, K. Deshpande, F. Arfuso, P. Newsholme, and A. Dharmarajan, “Cancer stem cell metabolism: A potential target for cancer therapy,” Molecular Cancer, vol. 15, no. 1, article no. 69, 2016. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Peiris-Pagès, U. E. Martinez-Outschoorn, R. G. Pestell, F. Sotgia, and M. P. Lisanti, “Cancer stem cell metabolism,” Breast Cancer Research, vol. 18, no. 1, article no. 55, 2016. View at Publisher · View at Google Scholar